Linklaters advises Aptar on entering into exclusive negotiations regarding a potential acquisition of Voluntis
Linklaters has advised Aptar, a global leader in drug delivery, consumer product dispensing and active material science solutions, on its entry into exclusive negotiations with respect to a potential acquisition of all outstanding shares of Voluntis, a pioneer in digital therapeutics whose shares are listed on the Euronext Growth market in Paris. This acquisition would complement Aptar's existing digital health portfolio of connected devices by adding digital therapeutic solutions and broadening its digital health services across multiple chronic conditions and diseases.
Signature of the final acquisition agreement for a block of approximately 64% of Voluntis' share capital would occur following completion of the consultation procedure of the employee representative bodies of Voluntis. The completion of the transfer of the block of shares would be subject to customary conditions and notably the approval of the French Ministry of Economy under the foreign investment clearance regulations.
The acquisition of the controlling interest will be followed by a simplified tender offer for the remaining outstanding Voluntis shares.
The Linklaters team was led by Partner Pierre Tourres and included Thomas Pontacq, Counsel, Véra Maramzine, Senior Associate and Espérance Ait Bachir, Associate in Corporate; Pierre Sikorav, Senior Associate and Claire Oualid, Associate in Energy & Infrastructure on the foreign investment aspects; Géric Clomes, Partner, Anne Cognet, Senior Associate and Cécile Romanin, Associate, on employment law aspects; Anne Wachsmann, Partner and Matthieu Blayney, Senior Associate, on competition law aspects; Sonia Cissé, Counsel, and Julia Loiseau on technology and data protection aspects.